Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Omeprazole Competition: Schwarz Offers Retroactive Discounts

  • News

Executive Summary

Schwarz Pharma is responding to competition in the generic omeprazole market by offering retroactive discounts to wholesalers on its generic version of AstraZeneca's Prilosec

You may also be interested in...



Schwarz Coping With Omeprazole Competition; Parcopa Is Next Launch

Schwarz' levodopa/carbidopa rapid dissolve formulation Parcopa will be the company's first attempt to convert its omeprazole windfall into a larger presence in the U.S. market

Schwarz Coping With Omeprazole Competition; Parcopa Is Next Launch

Schwarz' levodopa/carbidopa rapid dissolve formulation Parcopa will be the company's first attempt to convert its omeprazole windfall into a larger presence in the U.S. market

GSK Wellbutrin XL Launch Not Affected By Lost Shipment, Biovail Says

GlaxoSmithKline's ongoing launch of Wellbutrin XL will not be affected by the loss of a product shipment from Biovail's manufacturing facility, Biovail assured analysts during an Oct. 3 teleconference

Table

View full table

Tags:
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS042624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By